James Markert

Dr. James Markert

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
BGBrian J Gebhardt
Brian J Gebhardt
MDMichael C Dobelbower
Michael C Dobelbower
WEWilliam H Ennis
William H Ennis
ABAsim K Bag
Asim K Bag
JMJames Markert
James Markert
JFJohn B Fiveash
John B Fiveash
To analyze patterns of failure in patients with glioblastoma multiforme (GBM) treated with limited-margin radiation therapy and concurrent temozolomide. We hypothesize that patients treated with margins in accordance with Adult Brain Tumor Consortium guidelines (ABTC) will demonstrate patterns of failure consistent with previous series of patients treated with 2–3 cm margins.

1 June 2016 in Human Gene Therapy Clinical Development
Verified
Journal Article
Closed access
DPDaxa M. Patel
Daxa M. Patel
PFPaul M. Foreman
Paul M. Foreman
LNLouis Nabors
Louis Nabors
KRKristen O. Riley
Kristen O. Riley
GGG. Yancey Gillespie
G. Yancey Gillespie
JMJames Markert
James Markert
M032 is a second-generation oncolytic herpes simplex virus (oHSV) that selectively replicates in tumor cells. M032 kills tumor cells directly through oncolytic replication and then proceeds to infect tumor cells in proximity, continuing the process of tumor destruction. In addition to this direct oncolytic activity, the virus carries a therapeutic payload—thus acting as a gene therapy vector—and causes the tumor cell to synthesize and secrete the immunity-stimulating protein interleukin-12 (IL-12) before cell death.1 Human IL-12 is expressed and promotes an immune response against surviving tumor cells, increasing the antitumor effect of the therapy. IL-12 also produces an antiangiogenic effect, by interfering with the production of new tumor blood vessels necessary for tumor growth. Thus, M032 oHSV exerts antitumor effects through three distinct potential mechanisms. The virus has also been genetically engineered to minimize toxic effects for the patient. Preclinical animal models support the safety of intracranial inoculation with M032 in two relevant species (mouse and nonhuman primate). This clinical protocol outlines the dose-escalating phase I study for evaluation of M032 in patients with recurrent or progressive malignant glioma.

6 March 2017 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
PFPaul M. Foreman
Paul M. Foreman
GFGregory Friedman
Gregory Friedman
KCKevin A. Cassady
Kevin A. Cassady
JMJames Markert
James Markert

16 January 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JLJustin T. Low
Justin T. Low
MBMichael Brown
Michael Brown
ZRZachary J Reitman
Zachary J Reitman
JBJoshua Bernstock
Joshua Bernstock
JMJames Markert
James Markert
DADavid M. Ashley
David M. Ashley
Since the discovery that cGAS/STING recognizes endogenous DNA released from dying cancer cells and induces type I interferon and antitumor T cell responses, efforts to understand and therapeutically target the STING pathway in cancer have ensued. Relative to other cancer types, the glioma immune microenvironment harbors few infiltrating T cells, but abundant tumor-associated myeloid cells, possibly explaining disappointing responses to immune checkpoint blockade therapies in cohorts of patients with glioblastoma. Notably, unlike most extracranial tumors, STING expression is absent in the malignant compartment of gliomas, likely due to methylation of the STING promoter. Nonetheless, several preclinical studies suggest that inducing cGAS/STING signaling in the glioma immune microenvironment could be therapeutically beneficial, and cGAS/STING signaling has been shown to mediate inflammatory and antitumor effects of other modalities either in use or being developed for glioblastoma therapy, including radiation, tumor-treating fields, and oncolytic virotherapy. In this Review, we discuss cGAS/STING signaling in gliomas, its implications for glioma immunobiology, compartment-specific roles for STING signaling in influencing immune surveillance, and efforts to target STING signaling — either directly or indirectly — for antiglioma therapy.

2 August 2004 in Cancer
Verified
Journal Article
Open access
PDF file
ARAndrew E. Radbill
Andrew E. Radbill
JFJohn F. Fiveash
John F. Fiveash
EFElizabeth T. Falkenberg
Elizabeth T. Falkenberg
BGBarton L. Guthrie
Barton L. Guthrie
PYPaul E. Young
Paul E. Young
JMJames Markert
James Markert
BACKGROUND: Melanoma is the primary malignancy that is most likely to metastasize to the brain. Because such an event carries an almost uniformly poor prognosis, the current study reviewed outcomes and identified associated prognostic indicators for 51 consecutive patients receiving gamma knife (GK) radiosurgery in the initial treatment of 188 intracranial melanoma metastases.METHODS: Data were collected retrospectively from a single‐center GK radiosurgery database and from primary patient medical records and radiographs.RESULTS: At presentation, 71% of patients had multiple intracranial metastases, and extracranial metastases were present in 66% of patients. Thirty‐two patients (63%) were initially treated with GK radiosurgery alone, whereas the remainder received GK radiosurgery in combination with surgery and/or whole‐brain radiotherapy (WBRT). Overall median survival from time of GK radiosurgery was 26 weeks. Subgroup analysis revealed a median survival of 77 weeks for patients presenting with a single lesion, compared with 20 weeks for patients presenting with multiple lesions (P = 0.003). Patients in recursive partitioning analysis (RPA) Class I survived a median of 57 weeks, compared with a median survival of 20 weeks for patients in RPA Class II or III (P = 0.002). Although long‐term imaging follow‐up revealed that a majority of patients experienced distant brain metastases, multivariate analysis showed that distant metastases occurred significantly sooner in patients with extracranial metastases (P = 0.0004). Addition of initial WBRT had no significant effect on the time to development of new brain metastases (P = 0.13). Local control (crude) was observed in 81% of lesions initially treated with GK. Patients experienced improved or stable symptoms for a median of 37 weeks post–GK radiosurgery.CONCLUSIONS: Survival analyses supported the use of GK radiosurgery in the initial treatment of patients with melanoma brain metastases, with best results occurring in patients presenting with a single lesion. Cancer 2004. © 2004 American Cancer Society.

1 May 2012 in Journal of Virology
Verified
Journal Article
Closed access
JMJames Markert
James Markert
JCJames J. Cody
James J. Cody
JPJacqueline N. Parker
Jacqueline N. Parker
JCJennifer M. Coleman
Jennifer M. Coleman
KPKathleen H. Price
Kathleen H. Price
RWRichard J. Whitley
Richard J. Whitley
Herpes simplex virus 1 (HSV-1) mutants that lack the γ 1 34.5 gene are unable to replicate in the central nervous system but maintain replication competence in dividing cell populations, such as those found in brain tumors. We have previously demonstrated that a γ 1 34.5-deleted HSV-1 expressing murine interleukin-12 (IL-12; M002) prolonged survival of immunocompetent mice in intracranial models of brain tumors. We hypothesized that M002 would be suitable for use in clinical trials for patients with malignant glioma. To test this hypothesis, we (i) compared the efficacy of M002 to three other HSV-1 mutants, R3659, R8306, and G207, in murine models of brain tumors, (ii) examined the safety and biodistribution of M002 in the HSV-1-sensitive primate Aotus nancymae following intracerebral inoculation, and (iii) determined whether murine IL-12 produced by M002 was capable of activating primate lymphocytes. Results are summarized as follows: (i) M002 demonstrated superior antitumor activity in two different murine brain tumor models compared to three other genetically engineered HSV-1 mutants; (ii) no significant clinical or magnetic resonance imaging evidence of toxicity was observed following direct inoculation of M002 into the right frontal lobes of A. nancymae ; (iii) there was no histopathologic evidence of disease in A. nancymae 1 month or 5.5 years following direct inoculation; and (iv) murine IL-12 produced by M002 activates A. nancymae lymphocytes in vitro . We conclude that the safety and preclinical efficacy of M002 warrants the advancement of a Δγ 1 34.5 virus expressing IL-12 to phase I clinical trials for patients with recurrent malignant glioma.